The Vera Health Series A funding, announced on 27 October 2026, puts $28.5 million behind a clinical AI search engine that says it already serves more than 800,000 clinicians in 190 countries. The round was led by Threshold Ventures and brings the company’s reported total funding to $32 million. Vera describes its product as a tool that finds and grades medical evidence for clinicians. This article explains what the company says it does, how it differs from autonomous clinical decision-making, and which claims are company-reported and unverified.
Key takeaways from the Vera Health Series A funding
- Vera Health raised a $28.5 million Series A led by Threshold Ventures, for reported total funding of $32 million.
- Existing investors Y Combinator and Gradient are reported to have invested more; other participants named in reports include Mantis VC and SV Angel, and one report also names Optum Ventures.
- The company says more than 800,000 clinicians in 190 countries use the platform; these figures are company-reported.
- Vera says it retrieves and grades evidence before answering and that it does not make clinical recommendations.
- It says the product stays free for licensed clinicians and trainees, with revenue coming from hospitals and institutions.
What Vera Health does, and what the Vera Health Series A funding will pay for
Vera Health calls itself a clinical AI search engine. According to the company, it searches more than 60 million peer-reviewed papers, clinical guidelines, consensus statements and drug labels, grades the evidence, and gives an answer with each claim linked to its source and colour-coded by strength. Funds from the round are described as going toward clinical evidence infrastructure, international expansion, partnerships with medical societies, publishers and health systems, and deeper integration of local guidelines and hospital protocols. The company has not itemised the spending. Team size is reported at 12 employees.
Evidence retrieval is not clinical decision-making in the Vera Health Series A funding
The distinction matters. A search tool that finds and ranks evidence supports a clinician who then decides what to do; an autonomous decision system would recommend or take actions itself. Vera says its product supports clinical judgement and does not make clinical recommendations. How regulators view software that supports decisions depends on what it does and how it is presented, and the FDA publishes its approach on its clinical decision support software page. We have not seen any regulatory filing for Vera, and the reports do not describe one.
How Vera says it grades evidence, per the Vera Health Series A funding reports
Reports say the platform weighs study design, sample size, cohort power, recency, journal impact and citation patterns, checks for retractions and highlights conflicting studies or guidelines instead of giving a single answer. It also says it prioritises local guidance, such as French and European guidelines for French users, and offers a feature called Vera Spaces that lets hospitals index their own protocols. It says automated evaluators, trained on blinded clinical reviews, check real responses daily and escalate safety concerns to a human team. These are company descriptions and we have not tested them.
Adoption claims behind the Vera Health Series A funding
The company says the 800,000 clinicians include about one in four practising physicians in Spain and Italy and one in seven in France, and that growth came mainly through peer referrals without a marketing budget. None of these numbers has been independently verified, and “user” in this context may mean anyone who has signed in, not active daily clinicians. Investors typically weigh such figures against retention and usage data that the company has not published.
Privacy and compliance claims in the Vera Health Series A funding
Vera says it is HIPAA and GDPR compliant and SOC 2 Type II certified, and that it does not train its models on clinicians’ entered patient queries. US health privacy rules are explained by the US Department of Health and Human Services. Certifications relate to security controls and do not themselves prove clinical accuracy.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s AI in Healthcare Market report values the global market at USD 41.84 billion in 2025 and projects USD 1,136.90 billion by 2035, a CAGR of 39.1% from 2026 to 2035. It says North America held 43% in 2025, Asia Pacific is the fastest-growing region at a projected 42.5%, clinical AI was 42% of applications and healthcare providers were 46% of end users. The page was last updated in June 2026. These are global estimates and do not measure Vera. See our Healthcare IT section.
Timeline of the Vera Health Series A funding
- 27 October 2026: Vera Health announces the $28.5 million Series A.
- Rolling out: Vera Spaces, for hospital-specific protocols.
General background: why clinicians use evidence search
Clinicians face a flood of research and guidelines, and time at the point of care is short. Evidence search tools aim to speed up finding trustworthy answers, but they carry risks if answers are wrong or out of date, which is why transparency about sources and evidence strength is central.
Our analysis of the Vera Health Series A funding
In our assessment, the Vera Health Series A funding is a bet that clinicians will pay, through their institutions, for a tool they already use for free. The key tests are whether the grading is reliable, whether hospitals buy integrated versions and whether regulators see the product as support or as decision-making. We do not give investment advice.
What is not disclosed in the Vera Health Series A funding
- Valuation and investor ownership.
- Revenue and the number of paying institutions.
- Independent accuracy testing.
- Active usage and retention data.
Risks and caveats of the Vera Health Series A funding
Adoption figures and product claims come from the company. AI tools can make errors, and clinicians remain responsible for decisions. This article is news reporting and not medical or investment advice.
What to watch next after the Vera Health Series A funding
- Publication of accuracy studies.
- Hospital deals for Vera Spaces.
- Any regulatory comment on the product category.
FAQ
Who led the round?
Threshold Ventures led the $28.5 million Series A.
Does Vera make clinical decisions?
The company says it does not make clinical recommendations; it retrieves and grades evidence.
Is it free?
The company says it is free for licensed clinicians and trainees.
How we reported this: we relied on company-reported information as relayed in press accounts, regulator pages and the Acumen Research and Consulting report cited above. Last updated 29 October 2026. This is news reporting and not advice.